Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Combination Therapy for Pulmonary Tuberculosis (TB)

Clinical Trial ID NCT01638520

Rank	Title	Journal	Year	PubWeight™‹?›
1	Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis.	BMC Med	2016	0.83